Amgen posts upbeat assessment of PhII KRAS data on AMG510 — but there's no clear picture of what researchers saw
It’s not unusual to be left wanting after reading a top-line press release on closely-watched trial data. But Amgen is taking it to a whole new level with its Phase II snapshot on the KRAS G12c drug sotorasib — aka AMG 510.
The drug’s one solid shot at breakthrough status is in lung cancer, where researchers found evidence of efficacy in early-stage work. Now, they’re up to Phase II data, which execs earlier maintained could pave the way to a quick OK, and the team is giving little away.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.